Sort   by:  
 Page size 
TranscriptomicsResponse of Escherichia coli to acetate in presence of 100 mM methyl α-D-glucopyranoside
This experiment was performed to challenge E. coli response to acetate when its growth rate flux is reduced by 40% with 100 mM methyl α-D-glucopyranoside. Control without inhibition in the exact same conditions was already published on ArrayExpress database (accession number E-MTAB-9086) and could ...
ORGANISM(S): Escherichia coli K-12 
2022-09-23 | E-MTAB-11717 | biostudies-arrayexpress
TranscriptomicsResponse of Escherichia coli to acetate concentration during growth on glucose
E. coli MG1655 was grown on M9 minimal medium supplemented with 15mM glucose and either 0, 10, 50 or 100 mM acetate. Transcriptomic analysis from exponential growing cells was performed using Agilent microarray A-MEXP-2232. This work was done with the help of students during practicals. Consequentl...
ORGANISM(S): Escherichia coli str. K-12 substr. MG1655 
2020-08-21 | E-MTAB-9086 | biostudies-arrayexpress
TranscriptomicsEffect of acetate during Escherichia coli switch from N-Acetyl Glucosamine to Malate
This experiment was performed to challenge E. coli response to acetate when switched from N-Acetyl Glucosamine (NAG) to malate as the main substrate. Here, E. coli BW25113 strain was grown in M9 medium complemented with 15 mM NAG, The cells were grown to mid-exponential phase in shake flasks at 37...
ORGANISM(S): Escherichia coli K-12 
2026-05-12 | E-MTAB-16650 | biostudies-arrayexpress
UnknownA Meta-Analysis of α-Synuclein Multiplication in Familial Parkinsonism.
Not available
S-EPMC6297377 | biostudies-literature
UnknownNivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study.
Not available
S-EPMC6864847 | biostudies-literature
UnknownNivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up.
Not available
S-EPMC10500465 | biostudies-literature
UnknownPhase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
Not available
S-EPMC5791843 | biostudies-literature
UnknownThe two pore potassium channel THIK-1 regulates NLRP3 inflammasome activation.
Not available
S-EPMC9314991 | biostudies-literature
UnknownA pathogenic variant in RAB32 causes autosomal dominant Parkinson's disease and activates LRRK2 kinase.
Not available
S-EPMC10827257 | biostudies-literature
UnknownFive-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.
Not available
S-EPMC5746164 | biostudies-literature
Sort   by:  
 Page size